Age-related macular degeneration (AMD) is the major cause of legal blindness in developed countries. Intermediate AMD represents the most frequent stage. However, it often evolves towards complicated stages, namely neovascular AMD or geographic atrophy (GA). Despite the available treatments, the visual outcome is highly heterogeneous. The scientific interest is growing regarding the assessment of neuroretinal changes in AMD. Although AMD is mainly considered an outer retinal disease, recent evidence suggests a major involvement of retinal glia and neurons, i.e. an involvement of the inner retina. This damage may remarkably affect the morphological and functional AMD outcome, subverting retinal signal transmission cascade and more clearly explaining the outcome of the disease. The main goal of this study is to perform a multidisciplinary, multicenter, both prospective and retrospective evaluation of neuroretinal degeneration in different AMD stages in preclinical and clinical models.
Confirmed diagnosis of AMD
low BCVA (<20/100)
other ocular diseases
uncontrolled systemic diseases potentially affecting data interpretation
Patients affected by intermediate, wet and dry (geographic atrophy) age-related macular degeneration (AMD) and healthy age- and gender-matched controls
Case-control
Prospective
Not listed
Neuroretinal degeneration quantitative metrics
Quantitative multimodal retinal imaging metrics associated with inner retinal changes and neuroretinal degeneration
Imaging metrics of neuroretinal changes
Multimodal retinal imaging metrics associated with inner retinal changes and neuroretinal degeneration
MicroRNA profiles associated with AMD stages
MicroRNAs different profiles associated with AMD stages, risk of progression and neuroretinal degeneration.
Click on the lead sponsor to view all of their trials.
IRCCS San Raffaele
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
